Orexigen Therapeutics
OREX
OREX was delisted on the 3rd of April, 2018.
121 hedge funds and large institutions have $164M invested in Orexigen Therapeutics in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 22 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% less funds holding
Funds holding: 132 → 121 (-11)
11.38% less ownership
Funds ownership: 77.08% → 65.69% (-11%)
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
46% less call options, than puts
Call options by funds: $961K | Put options by funds: $1.77M
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
67% less capital inflows, than outflows
Capital inflows: $20.7M | Capital outflows: $62.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Foresite Capital Management II
Larkspur,
California
|
+$4.77M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.47M |
| 3 |
Baupost Group
Boston,
Massachusetts
|
+$3.45M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Spark Investment Management
New York
|
+$909K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.1M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
-$3.17M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.89M |
| 4 |
Next Century Growth Investors
Plymouth,
Minnesota
|
-$2.44M |
| 5 |
Renaissance Technologies
New York
|
-$2.42M |
OREX Hedge Fund Activity: Q4 2015 in Review
121 of the 3,823 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics (OREX) for Q4 2015, worth a combined $164M — down 30% from $236M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of OREX and 9 opened new positions — a net loss of 13 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Foresite Capital Management II, adding an estimated $4.77M. The largest seller was State Street, cutting an estimated $24.1M.
- 121 institutional investors held Orexigen Therapeutics (OREX) as of Q4 2015, down from 132 in Q3 2015.
- Funds reported $164M of Orexigen Therapeutics stock for Q4 2015, down 30% quarter-over-quarter.
- 9 funds opened new Orexigen Therapeutics positions in Q4 2015 and 22 closed out, a net change of -13 holders.
- The largest Orexigen Therapeutics buyer in Q4 2015 was Foresite Capital Management II, an estimated $4.77M added.
- The largest Orexigen Therapeutics seller in Q4 2015 was State Street, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2015.